

2023/2024 Reporte de Impacto

Progreso

Para ver nuestro reporte completo haga click [aquí](#).



"Ampliar y permitir el acceso a nuestros medicamentos y vacunas para los cientos de millones de personas en todo el mundo que dependen de nosotros es tanto una gran responsabilidad como un profundo privilegio. Impulsados por un sentido inquebrantable de urgencia y alimentados por un enfoque implacable en la ciencia de vanguardia, seguiremos ofreciendo soluciones innovadoras que aborden algunos de los desafíos de salud globales más graves del mundo y brinden valor a la sociedad."

Robert M. Davis
Chairman & Chief Executive Officer

Key highlights



Acceso a la Salud

>550 millones

Personas alcanzadas con nuestras vacunas y medicinas en 2023¹

240 millones

Personas accedieron a nuestras vacunas y medicamentos innovadores a través de soluciones de acceso en 2023²



Empleados

>99%

La paridad indicada en nuestro estudio global de equidad salarial para empleadas en comparación con sus colegas masculinos. Por tercer año consecutivo, hemos mantenido una equidad salarial mayor al 99% por raza y género en los Estados Unidos.



Sostenibilidad Ambiental

Net-zero hacia 2045

Comprometidos con un objetivo de emisiones netas cero de gases de efecto invernadero (GEI) en todas nuestras operaciones globales (Alcances 1, 2 y 3) para 2045, alineado con las directrices de la iniciativa de Objetivos Basados en la Ciencia (SBTi).



Etica & Valores

\$3.600 millones

Inversión en proveedores globales diversos de Tier 1 y 2 en 2023

Nuestro Impacto

Por más de 130 años, nos hemos dedicado a operar de manera responsable, creando valor para la sociedad. Este compromiso es una de nuestras fortalezas y es fundamental para nuestro negocio, por eso operar de manera responsable es parte de la base de nuestro Marco Estratégico, que representa nuestro compromiso de promover un futuro seguro, sostenible y saludable para las personas y las comunidades.

Nuestro Propósito

Utilizamos el poder de la ciencia de vanguardia para salvar y mejorar vidas en todo el mundo.

Nuestra Visión

Aspiramos a ser la principal empresa biofarmacéutica intensiva en investigación.

Nuestro Marco Estratégico

Nuestras Prioridades Estratégicas

Invertir, ampliar y acelerar nuestro canal de productos para ofrecer productos que cambien la vida.

Demostrar valor a nuestros interesados y extender el acceso a soluciones que aborden necesidades médicas no satisfechas.

Fomentar la innovación y la productividad habilitadas por lo digital y los datos.

Invertir en el crecimiento, éxito y bienestar de nuestras personas

Our Ways of Working



Ganar como un equipo



Foco en lo importante



Actuar con urgencia



Experimentar, aprender y adaptarse



Abrazar la Diversidad y la Inclusión



Estar abiertos y alzar la voz

Valores



Primero el Paciente



Ética e Integridad



Respeto por las Personas



Innovación y Excelencia Científica

Operamos de manera responsable todos los días en nombre de la sociedad, accionistas y de todos nuestros aliados para permitir un futuro seguro, sostenible y saludable para las personas y comunidades en todas partes

Nuestras áreas ,objetivos y performance

Nuestros objetivos representan los compromisos públicos asumidos para entregarle valor a la sociedad. Durante el último año, nos desafiamos a nosotros mismos para seguir avanzando significativamente hacia esos ambiciosos compromisos en cada una de nuestras áreas de enfoque.



Acceso a la Salud

Objetivos	2022	2023	Total
Permitir que 350 millones de personas más accedan a nuestros medicamentos y vacunas innovadoras a nivel mundial, a través de soluciones de acceso, para 2025. ²	189.2	240.0	N/A
Alcanzar al menos el 75% de los países en el mundo anualmente con nuestros productos. ³	76%	79%	N/A
Avanzar aún más en la equidad en salud alcanzando a 50 millones de personas en países de ingresos bajos y medianos (LMICs) y las personas desatendidas por la atención médica en países de ingresos altos con nuestras inversiones sociales, para 2025. ^{4,5}	18.6	21.2	54.8 (2021-2023)



Empleados

Objetivos	2022	2023
Mantener o incrementar nuestro índice de inclusión al 2025. ^{6,7}	On track	On track
Mantener o incrementar el índice de compromiso de nuestros empleados al 2025. ^{6,7}	On track	On track



Sostenibilidad Ambiental

Objetivos	2022	2023
Reducir nuestro emisiones de gases de efecto invernadero en el scope 1 y 2 en un 46% para 2030, con base al 2019. ⁸	8% debajo de la base ⁹	12% debajo de la base
Reducir nuestros gases de efecto invernadero en la cadena de valor (Scope 3) en un 30% para 2030, con base al 2019. ¹⁰	6% encima de la base	4% encima de la base
Contar con el 100% de nuestra electricidad adquirida de fuentes renovables para el 2025. ¹¹	45%	57%
Cero emisiones de gases de efecto invernadero (Scopes 1, 2 & 3) al 2045.	En 2024, nos comprometimos a un target de cero impacto al 2045 entre todas nuestras operaciones globales (GHG emissions Scope 1, 2 & 3) alineado con las guías de SBTi.	



Etica & Valores

Objetivos	2022	2023
Fomentar una cultura de "Alzar la Voz" manteniendo o superando nuestro porcentaje actual de empleados a nivel mundial que responden favorablemente a la pregunta de "Dispuesto a informar" en la encuesta interna, para 2025 ^{12,13}	On track	On track
Fomentar una cultura Mantener el cumplimiento del 100% de los requisitos de privacidad y protección de datos para el monitoreo activo de incidentes, análisis de riesgos/daños y notificación oportuna de violaciones de datos. ¹⁴	100% compliance maintained	100% compliance maintained



Premios y reconocimientos

Estamos orgullosos de que nuestro compromiso con impulsar acciones responsables haya recibido reconocimiento externo mientras nos esforzamos por mitigar riesgos relacionados con la sostenibilidad y crear valor para nuestro negocio, la sociedad y todos nuestros grupos de interés.

Barron’s

100 compañías mas sustentables: U.S.Companies #38 overall and #1 in the biopharmaceutical industry (2024)

Human Rights Campaign Foundation

Reconocida por: the Corporate Equality Index (2023-2024)

Newsweek

Compañía Americana más responsable— #1 en general y #1 ien el sector (2024)

Seramount

Una de las 75 empresas en la lista de las Mejores Empresas para: Executive Women list (2023)

JUST Capital

Las empresas más JUSTAS de Estados Unidos #25 overall and #1 in the sector (2024)

TIME

#28 compañías mas sostenibles del mundo (2024)



¹ This people reached metric estimates the number of people who have received a MSD product through commercial channels, clinical trials, voluntary licensing and product donations. Product donations include people reached through the MECTIZAN Donation Program, U.S. Patient Assistance Programs, and the MSD Medical Outreach Program. Sources of data are MSD and third-party data sets that are tracked within an enterprise-wide internal database. The people reached metric for all sources is calculated as doses sold divided by the average dose schedule for a given market in a given year. People taking multiple products may be counted as multiple people toward the total estimate. In some instances, this estimate may include people enabled to access our products through access solutions, which are calculated as part of our goal to enable access to our innovative medicines and vaccines. The people reached metric does not include people reached through social investments, which are calculated as part of our goal to further advance health equity for populations in LMICs and underserved by health care in high-income countries.

² Metrics contributing to this goal are displayed on an annual basis and provide information on the number of people we estimate now have the option to access medicines and vaccines as a result of our sustainable access strategies, solutions and partnerships. These solutions include our commitment to Gavi and UNICEF (rather than doses shipped), collaborations to optimize resources in health systems, expanded financial coverage through insurance, and new community-based channel partnerships. “Innovative medicines and vaccines” refers to our Company’s on-patent products. Enable “more people” is defined as populations supported by initiatives implemented and launched in market and will be in comparison to the baseline (2020) as of 2025. Evidence for metrics is sourced from publicly available data and proxy sources by market. While proxies differ by market, all methodologies are evaluated and represent our best estimate of people enabled to access innovative medicines and vaccines. People who were enabled to access innovative medicines and vaccines did not necessarily receive such innovative medicines and vaccines.

³ Countries are as defined by the World Bank Country and Lending Groups. Includes only human health products.

⁴ Social investments include our Company’s philanthropic partnerships, programs and impact investments. Underserved populations are defined as those that face health disparities due to disadvantages related to insurance status, social determinants of health, race, ethnicity, gender identity/sexual orientation, age and/or language preference. The goal is cumulative across the reporting period of 2021-2025, and is independent of a baseline period. Actuals for each year to date are based on reports received between 1 March and the last day of February of the corresponding performance year.

⁵ Third-party reporting is used to calculate the number of people reached through social investments. In some cases, third-party reports may include cumulative people reached for the reporting period, and/or data that is attributable to other partners as well as our Company’s philanthropic investment.

⁶ In 2022, we revised employee survey measurements to align with evolving best practices. In this report, 2022 data are used as the baseline for future comparison.

⁷ The Pulse survey is open to employees globally.

⁸ Scope 1 GHG emissions as direct emissions from owned or controlled sources such as on-site fuel combustion and fleet vehicles. Scope 2 GHG emissions are indirect emissions from the generation of purchased energy consumed by the reporting company.

⁹ In accordance with the World Resource Institute’s GHG Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired, sold or spun-off. Adjustments also reflect changes in methodology to ensure consistency from year to year, including Scope 2 emission factor updates [E-GRID (2023), IEA (2023), EU Residual (2023), UK Defra (2023) & Inventarios Corporativos (2023)] and Scope 1 & 3 emission factor updates [EPA Climate Leaders (2023)].

¹⁰ Scope 3 GHG emissions include all other indirect emissions in a company’s value chain.

¹¹ We have defined “purchased electricity” as electricity sourced from external suppliers as well as renewable electricity that was generated and utilized on-site where we retained the renewable attributes or where we have obtained renewable attributes through contract.

¹² Favorable response indicates the percentage of respondents who respond “yes” to the question stating, “I am willing to report employee misconduct and potential ethics or compliance issues.”

¹³ In 2021, we developed the “Willingness to Report” question referenced in footnote 1 to align with evolving best practices. This question was first included in the internal survey in March 2022, and 2022 data are used as the baseline against which 2023 data are compared.

¹⁴ Regulatory requirements differ by region.



Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.

Forward-looking statement

This publication of Merck & Co., Inc., Rahway, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No duty to update

The information contained in this publication was current as of the date presented. The Company assumes no duty to update the information to reflect subsequent developments. Consequently, the Company will not update the information contained in this publication and investors should not rely upon the information as current or accurate after the presentation date.

Merck & Co., Inc.
126 East Lincoln Avenue
P.O. Box 2000
Rahway, NJ 07065 USA
MSD.com

Merck & Co., Inc., Rahway, NJ, U.S.A., is known as MSD outside the United States and Canada.